Brief: Newron Reports 1 Year Results Of Study 014/15 In Treatment-Resistant Schizophrenia
04/01/2024 12:45
Jan 4 (Reuters) - Newron Pharmaceuticals SpA NWRN.S :
* NEWRON REPORTS EXCEPTIONAL ONE-YEAR RESULTS OF STUDY
014/15 WITH
EVENAMIDE IN TREATMENT-RESISTANT SCHIZOPHRENIA (TRS)
* MORE THAN 70% OF PATIENTS EXPERIENCED CLINICALLY IMPORTANT
REDUCTION IN DISEASE SEVERITY
* 25% OF ALL PATIENTS ACHIEVED "REMISSION"
* EVENAMIDE TREATMENT DEMONSTRATED SIGNIFICANT, CLINICALLY
IMPORTANT, PROGRESSIVE, SUSTAINED AND LONG-LASTING IMPROVEMENT
Source text for Eikon: ID:nBw14vgKla
Further company coverage: NWRN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study